The use of Blow-Fill-Seal technology, enables single doses without RNase, which may be sterile if necessary.
Through its 5 BFS plants on three continents (in France, United States and China) and an R&D development center, Unither is able to manage full diluent or reagent development from production to production.
In Unither Pharmaceuticals
Based in Amiens, France, in 1993, Unither Pharmaceuticals has become a worldwide leader in the manufacture of drugs for generic pharmaceutical companies including but not limited to, eye drops and respiratory unit doses, solutions saline, and stick packs.
Unither Pharmaceuticals has 7 manufacturing sites and 1 R&D center France, United States, China and Brazil. These sites generated revenues of € 330 million in 2020 with a turnover of over 1,600 employees.
Seal Blow-Fill: https://www.unither-pharma.com/technologies-innovations/blow-fill-seal-bfs/?lang=en
Contact: [email protected]
SOURCE Unither Pharmaceuticals